Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2025
Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2025
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jul 2025
Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma
29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 20 Jul 2025
Amivantamab in combination with lazertinib for the first-line treatment of patients with advanced EGFR mutation positive non-small cell lung cancer
4 July 2025 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 17 Jul 2025
Thousands more breast cancer patients to benefit from new NHS treatment
17 July 2025 - NICE approves ribociclib combination therapy to help prevent cancer returning in early stage disease. ...
Posted by Michael Wonder on 13 Jul 2025
Zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma
10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...
Posted by Michael Wonder on 19 Jun 2025
Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy
19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...
Posted by Michael Wonder on 19 Jun 2025
Atezolizumab for the adjuvant treatment of patients with resected non-small-cell lung cancer
19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment ...
Posted by Michael Wonder on 18 Jun 2025
Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...
Posted by Michael Wonder on 12 May 2025
Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor
12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer ...
Posted by Michael Wonder on 09 May 2025
Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer
9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...
Posted by Michael Wonder on 14 Apr 2025
Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer
11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...